Pharmaxis Closes Share Purchase Plan
30 June 2009 - 10:12AM
PR Newswire (US)
SYDNEY, June 29 /PRNewswire-Asia/ -- Pharmaxis
(ASX:PXS)(NASDAQ:PXSL) today announced it had raised A$7.2 million
from its Share Purchase Plan which closed on 24 June 2009.
Shareholders of the company were given the opportunity to purchase
up to $5,000 worth of shares each at the $2.35 price paid by
institutional investors in the recent placement. A total of 1,584
shareholders participated in the plan under which the company will
issue approximately 3 million new shares and receive funds of
approximately $7.2 million. Dr Alan Robertson, Chief Executive
Officer of Pharmaxis said, "We are very encouraged and appreciative
of the level of support from our shareholders. The total proceeds
of the placement and share purchase plan of $54 million puts us in
a strong position from which to take our products to the global
markets." Shares will be issued today, 30 June 2009, and are
expected to be listed on the Australian Securities Exchange on 2
July 2009. Holding statements will be posted on or about 1 July
2009. Forward-Looking Statements The statements contained in this
media release that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations,
beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding the potential for Aridol and/or
Bronchitol. All forward-looking statements included in this media
release are based upon information available to us as of the date
hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future
events or otherwise. We cannot guarantee that any product candidate
will receive FDA or other regulatory approval or that we will seek
any such approval. Factors that could cause or contribute to such
differences include, but are not limited to, factors discussed in
the "Risk Factors and Other Uncertainties" section of our Form 20-F
lodged with the U.S. Securities and Exchange Commission. CONTACT:
Alan Robertson Chief Executive Officer Tel: +61-2-9454-7200 Email:
RELEASED THROUGH: Australia: Felicity Moffatt Tel: +61-418-677-701
Email: United States: Brandon Lewis Trout Group Tel:
+1-646-378-2915 Email: DATASOURCE: Pharmaxis Ltd CONTACT: Alan
Robertson, +61-2-9454-7200, ; Felicity Moffatt, +61-418-677-701, ,
both of Pharmaxis; Brandon Lewis of Trout Group for Pharmaxis,
+1-646-378-2915,
Copyright
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From Apr 2024 to May 2024
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ): 0 recent articles
More Pharmaxis Limited - Sponsored Adr (Australia) (MM) News Articles